Morepen Labs adds blockbuster Rivaroxaban, Vildagliptin, UDCA to API portfolio Farhat Nasim14 Oct 2019 1:36 PM ISTWhile two products Rivaroxaban and Vildagliptin will augment Morepen Lab's presence in the cardiac and diabetic segments respectively, the third...
NPPA fixes retail price of 18 commonly used formulations including Metformin, Atorvastatin; Details Farhat Nasim4 Jun 2019 5:44 PM ISTNew Delhi: Through a recent notification, the government regulatory agency, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail...
Pfizer gets USFDA nod for potential blockbuster heart drug Tafamidis Medical Dialogues Bureau7 May 2019 9:45 AM ISTPfizer, which has touted tafamidis as a potential blockbuster product, set a list price of $225,000 a year for the medicine, which would be sold under...
Alchem solves stability dilemma for micronized DIGOXIN; files PATENT for novel production process Meghna A Singhania16 April 2019 4:47 PM ISTAlchem's molecule is the sole micronized digoxin available globally that resolves the challenge of micro dosage formulation and the long-term...
Bayer, Johnson and Johnson's heart drug Xarelto fails trial to widen use Ruby Khatun Khatun28 Aug 2018 9:45 AM ISTFRANKFURT: Bayer and Johnson and Johnson's campaign to widen the market for its heart drug Xarelto hit a snag on Sunday when a study for a potential...
Novartis hopeful for novel heart drug, despite modest benefit Ruby Khatun Khatun28 Aug 2017 1:05 PM ISTZURICH: Novartis will seek regulatory approval this year for a new kind of anti-inflammatory heart drug, though some experts fear fatal infection...
